#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Ovarian cancer Dementia Alzheimer's type Colorectal cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Malignant melanoma Non-small cell lung cancer metastatic Asthma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Fatty acid oxidation disorder Cortical dysplasia Hypereosinophilic syndrome Mucopolysaccharidosis I Langerhans cell sarcoma Ischaemic stroke Meningococcal immunisation C3 glomerulopathy Multifocal motor neuropathy Marfan's syndrome Adenovirus infection Breast cancer Anti-neutrophil cytoplasmic antibody positive vasculitis Fibrosarcoma Adrenogenital syndrome More trials…

    Learn about Rare Diseases

    Wiskott-Aldrich syndrome – Life with Disease Kearns-Sayre syndrome – Treatment Adrenogenital syndrome – Treatment Mucous membrane pemphigoid – Life with Disease Haemolytic uraemic syndrome – Diagnostics Lymphangiosarcoma – Diagnostics Mucopolysaccharidosis I Undifferentiated sarcoma – Life with Disease Breast angiosarcoma metastatic – Life with Disease Rosai-Dorfman syndrome – Trials in Disease More diseases…
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Padeliporfin Imiquimod Clavulanic Acid Damoctocog Alfa Pegol Methylprednisolone Florbetapir (18F) Human Albumin Solution Satralizumab 64CU-PSMA I&T Anidulafungin Sym024 Doxycycline Hyclate Alks 2680 TUVATEXIB Clomifene Citrate Verapamil Hydrochloride Oregovomab Hydroxocobalamin Pelareorep Sodium Nitroprusside Dihydrate More therapies…

    Learn about Your Condition

    Myxofibrosarcoma Petit mal epilepsy Food allergy Congenital aplastic anaemia Arthroscopy Blood disorder High-grade B-cell lymphoma Adenocarcinoma of colon Retroperitoneal fibrosis Cachexia Anal cancer Extraskeletal ossification Pulmonary sarcoidosis Obsessive-compulsive disorder Thyroid cancer metastatic More diseases…
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. IRCCS Humanitas Research Hospital

IRCCS Humanitas Research Hospital

Via Alessandro Manzoni 56, Rozzano, 20089, Italy

Want to learn more about this study or check if you can participate? Contact us.

  • A study to evaluate the efficacy and safety of vixarelimab in patients with moderate to severe ulcerative colitis

    Not recruiting

    2 1 1
    Investigated drugs:
    • Methotrexate Sodium
    • Vixarelimab
    • Azathioprine
    Belgium Czechia France Germany Greece Italy +1

  • A study to evaluate the effect of olpasiran on major cardiovascular events in patients with atherosclerotic cardiovascular disease and high levels of lipoprotein(a)

    Not recruiting

    3 1
    Austria Belgium Bulgaria Czechia Denmark Estonia +16

  • Study of tuvusertib combined with niraparib or lartesertib for patients with ovarian cancer that worsened after previous PARP inhibitor treatment

    Not recruiting

    2 1 1 1
    Investigated diseases:
    • Ovarian cancer
    Investigated drugs:
    • 2-Amino-6-Fluoro-N-(5-Fluoro-4-(1-Methyl-1H-Imidazol-5-Yl)Pyridin-3-Yl)Pyrazolo[1,5-A]Pyrimidine-3-Carboxamide
    • Tuvusertib
    • Niraparib Tosilate Monohydrate
    Belgium Denmark France Germany Italy The Netherlands +2

  • Testing Drug Combinations with GSK4381562A, GSK6097608, GSK4428859 and Dostarlimab in Patients with PD-L1 Positive Head and Neck Cancer That Has Spread or Returned

    Not recruiting

    2 1 1 1
    Investigated drugs:
    • Dostarlimab
    • Gsk6097608
    • Human Igg1 Kappa Monoclonal Antibody Against Tigit
    Denmark Finland France Germany Greece Hungary +6

  • Study of Datopotamab Deruxtecan with or without Durvalumab compared to standard treatment for patients with Stage I-III triple-negative breast cancer who have remaining cancer after initial therapy

    Not recruiting

    3 1 1 1
    Investigated diseases:
    • Triple negative breast cancer
    Investigated drugs:
    • Capecitabine
    • Datopotamab Deruxtecan
    • Durvalumab
    Belgium Denmark France Germany Greece Italy +2

  • Study of TAK-279 and apremilast for adults with moderate to severe plaque psoriasis

    Not recruiting

    3 1 1
    Investigated drugs:
    • Apremilast
    • Zasocitinib
    Germany Italy Poland

  • Study of rilvegostomig, trastuzumab deruxtecan, and AZD0901 in patients with locally advanced resectable gastroesophageal cancer before and after surgery

    Not recruiting

    2 1 1
    Investigated diseases:
    • Oesophageal adenocarcinoma
    Investigated drugs:
    • Azd0901
    • Rilvegostomig
    • Trastuzumab Deruxtecan
    Italy Spain

  • Effectiveness and Safety of Rezafungin in Adults with Chronic Pulmonary Aspergillosis Who Have Limited Treatment Options

    Not recruiting

    2 1 1 1
    Investigated drugs:
    • Rezafungin Acetate
    Austria Belgium France Germany Hungary Italy +2

  • Comparison of Risankizumab and Vedolizumab for Treatment of Moderate to Severe Ulcerative Colitis in Adults Who Have Not Received Targeted Therapies

    Not recruiting

    3 1 1 1
    Investigated drugs:
    • Vedolizumab
    • Risankizumab
    Austria Bulgaria Croatia Czechia Estonia Finland +14

  • Study comparing empasiprubart versus intravenous immunoglobulin for treating adults with multifocal motor neuropathy

    Not recruiting

    3 1 1
    Investigated drugs:
    • Empasiprubart
    • Human Normal Immunoglobulin (Iv)
    Austria Belgium Czechia Denmark Estonia France +13
Previous Page
1 … 36 37 38 39 40 … 65
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!